MannKind Corp (MNKD) stock

MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30273% above fair value

$4.13−0.03 (-0.72%)

Close on Nov 13, 2026Market cap $1.33BP/E –Yield –

MannKind EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

MannKind's EV/EBITDA was 39.5× on Nov 11, 2026, against 17.0× a year earlier. Over the last 4 years it ranged from 0.8× to 70.2×, with a median of 18.6×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	39.5×	+21.3
2025	Dec 31, 2025	18.2×	−7.0
2024	Dec 31, 2024	25.2×	+20.1
2017	Oct 31, 2017	5.1×	–

Where these numbers come from

Parsed from the XBRL in MannKind's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Mar 3, 2017
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MNKD.

Compare: MNKD vs LQDA · MNKD vs XERS · MNKD vs IRWD · MNKD vs AMPH · MNKD vs OPK

Revenue growth31.7% · median 18.1%

Gross margin88.6% · median 56.6%

Operating margin-2.9% · median 12.7%

Net margin-18.1% · median -1.8%

Company	Revenue	Growth
AMPH	$745.79M	+3.1%
LQDA	$621.87M	+798.4%
OPK	$501.64M	-8.3%
MNKD	$413.37M	+31.7%
IRWD	$400.30M	+18.1%
XERS	$368.26M	+38.4%

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 241
Held by institutions: 56.7%
Auditor: Deloitte & Touche LLP
SEC CIK: 899460

Advertisement
300 × 250

See a number that looks wrong?

MannKind EV/EBITDA

EV/EBITDA at the end of each year

More MannKind figures